Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and maintained a price target of $22.
August 10, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Arcutis Biotherapeutics and maintained a price target of $22.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $22 price target indicates a positive outlook for Arcutis Biotherapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100